Gufic Biosciences Reports Strong Q2 FY27 Consolidated Results with PAT Up 39.5% YoY
Gufic Biosciences Ltd · Financial Result · 15 Nov 2026, 1:52 am
Gufic Biosciences Reports Strong Q2 FY27 Consolidated Results with PAT Up 39.5% YoY Gufic Biosciences reported consolidated revenue from operations of ₹28,827.30 lakh for the quarter ended 30th Sep'26, up 21.6% YoY from ₹23,705.45 lakh and up 10.5% QoQ from ₹26,081.80 lakh. Profit before tax rose 39.1% YoY to ₹3,144.74 lakh compared to ₹2,260.41 lakh in Q2 FY26. Consolidated net profit reached ₹2,346.89 lakh, registering a 39.5% YoY growth against ₹1,682.40 lakh in the prior-year period. Basic and diluted EPS improved to ₹2.34 from ₹1.68 YoY. For H1 FY27, net profit expanded 53.1% YoY to ₹4,578.17 lakh.
Original exchange filing (PDF)
More announcements from Gufic Biosciences Ltd
- Intimation of Audio Recording of Earnings Conference Call held on November 16, 2026 at 04:30 p.m. is attached herewith · 17 Nov 2026
- Investor Presentation is attached herewith · 15 Nov 2026
- Intimation for appointment of Additional Director (Non-Executive Independent Director) of the Company is attached herewith. · 15 Nov 2026
- Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 15 Nov 2026
- Outcome of the Board of Directors Meeting held on Saturday, November 14, 2026 is attached herewith. · 15 Nov 2026
- Intimation of Environmental, Social and Governance (''ESG'') Rating is attached herewith · 13 Nov 2026
- Intimation of Earnings Conference Call scheduled to be held on November 16, 2026 is attached herewith · 16 Nov 2026
- Gufic Biosciences Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 14 Nov 2026
